Skip to Main Content
David Johnson, M.D.

David Johnson, M.D.

Professor

Endowed Title
R. Ellwood Jones, M.D. Distinguished Professorship in Clinical Education
School
Medical School
Department
Internal Medicine

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    David H. Johnson, M.D. is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology-Oncology. A specialist in lung cancer, he holds the R. Ellwood Jones, M.D. Distinguished Professorship in Clinical Education.

    Dr. Johnson received his medical degree from the Medical College of Georgia and completed internal medicine residency training at Mary Imogene Bassett Hospital in Cooperstown, New York. He then completed advanced training through a fellowship in medical oncology at Vanderbilt University in Nashville.

    Certified by the American Board of Internal Medicine in internal medicine and medical oncology, he served on the faculties of the Medical College of Georgia and Vanderbilt University School of Medicine before joining the UT Southwestern faculty in 2010 as the Chair of Internal Medicine.

    Dr. Johnson’s research interests involve understanding the biology of lung cancer and improving treatment of this and other solid tumors. Over the course of his career he played a major role in the development of several therapeutic agents including paclitaxel (Taxol), bevacizumab (Avastin) and erlotinib (Tarceva) all of which are now FDA-approved for the treatment of lung cancer. He also played a role in the clinical development of G-CSF culminating in its FDA approval.

    His investigations have resulted in more than 450 publications in peer-reviewed journals and more than 50 book chapters and monographs. He served as editor for the textbooks Lung Cancer, Principles & Practice and the Textbook of Uncommon Cancer.

    He is a past Chair of the American Board of Internal Medicine (ABIM) Board of Directors, and of ABIM Medical Oncology Subspecialty Board. He has served as President of the American Society of Clinical Oncology (ASCO), where he helped advance the organization’s quality of care activity known as the Quality Oncology Practice Initiative (QOPI) and was instrumental in establishing ASCO’s Cancer Survivorship Program.

    Dr. Johnson also served on the Food and Drug Administration’s Oncology Drug Advisory Committee, as chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group and on the Board of Directors of the National Comprehensive Cancer Network, the International Association for the Study of Lung Cancer and the LiveSTRONG Foundation.

     

     

  • Education
    Medical School
    Medical College of Georgia at Augusta University (1976)
    Internship
    Mary Imogene Bassett Hospital (1976), Internal Medicine
    Residency
    University of South Alabama Medical Center (1979), Internal Medicine
    Fellowship
    Vanderbilt University Medical Center (1983), Hematology Oncology
  • Research Interest
    • Developmental therapeutics
    • Lung cancer therapeutics
  • Publications

    Star Featured Publications

    Featured Featured Featured Featured Featured Featured Featured
    Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
    Lancet 2014 May 383 9928 1561-71
    Clinical course of advanced non-small cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
    Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH J Clin Oncol 2010 28 949-54
    Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.
    NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J. The Lancet 2010 375 1267-77
  • Books

    Featured 

    Lung Cancer, Principles & Practice.

    Harvey I. Pass, David P. Carbone, David H. Johnson, John D. Minna, G. Scagliotti, Andrew T. Turrisi, eds. (Ed.) (2010). Philadelphia, Lippincott Williams & Wilkins

    Textbook of Uncommon Cancer - 4th ed

    D. Raghavan, C.D. Blanke, D.H. Johnson, P.L. Moots, G.H. Reaman, P.G. Rose, M.K. Sekeres; eds (Ed.) (2012). Hoboken, NJ, Wiley-Blackwell

  • Honors & Awards
    • Giants in Cancer Care Award
      (2019)
    • ASCO Distinguished Achievement Award
      (2016)
    • College of Arts & Sciences Hall of Fame, University of Kentucky
      (2015)
    • Master, American College of Physicians
      (2015)
    • Chairman, American Board of Internal Medicine Board of Directors
      (2013-2015)
    • Established Investigator Award, CPRIT
      (2010)
    • Association of American Physicians
      (2009)
    • Distinguished Southern Oncologist Award, Southern Association of Oncology
      (2006)
    • President, American Society of Clinical Oncology
      (2004-2005)
    • Alpha Omega Alpha
      (1975)
  • Professional Associations/Affiliations
    • American Association for Cancer Research
    • American College of Physicians
    • American Society of Clinical Oncology
    • Association of American Physicians
    • International Association for the Study of Lung Cancer